Cytochrome p450 2C inhibition reduces post-ischemic vascular dysfunction

Vascular Pharmacology

Volumn 43, Issue 4, 2005, Pages 213-219

  Hunter, Arwen L ^a   Bai, Ni ^a   Laher, Ismail ^a   Granville, David J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

CYP2C9; Ischemia reperfusion; Sulfaphenazole; Vascular dysfunction

Indexed keywords

ACETYLCHOLINE; CYTOCHROME P450 2C; CYTOCHROME P450 2C6; CYTOCHROME P450 2C9; HYDROETHIDINE; ISOPRENALINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; OXIDOREDUCTASE INHIBITOR; SULFAPHENAZOLE; SUPEROXIDE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY DIAMETER; ARTERY WALL; ARTICLE; BIOAVAILABILITY; BLOOD VESSEL TONE; CANNULA; CONTROLLED STUDY; CORONARY VASCULAR RESISTANCE; ENDOTHELIUM INJURY; ENZYME INHIBITION; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HYPOTHESIS; ISCHEMIA; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION; VASCULAR DISEASE; VASODILATATION;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; ETHIDIUM; FLUORESCENT DYES; HEART; ISCHEMIA; MALE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; STEROID 21-HYDROXYLASE; SULFAPHENAZOLE; VASCULAR DISEASES;

EID: 27744554496     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2005.07.005     Document Type: Article

References (28)

1. S. Earley, A. Pastuszyn, and B.R. Walker Cytochrome p-450 epoxygenase products contribute to attenuated vasoconstriction after chronic hypoxia Am. J. Physiol., Heart Circ. Physiol. 285 2003 H127 H136
2. S. Fichtlscherer, S. Dimmeler, S. Breuer, R. Busse, A.M. Zeiher, and I. Fleming Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease Circulation 109 2004 178 183
3. B. Fisslthaler, U.R. Michaelis, V. Randriamboavonjy, R. Busse, and I. Fleming Cytochrome P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression Biochim. Biophys. Acta 1619 2003 332 339
4. I. Fleming, U.R. Michaelis, D. Bredenkotter, B. Fisslthaler, F. Dehghani, R.P. Brandes, and R. Busse Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries Circ. Res. 88 2001 44 51
5. M. Freyss-Beguin, E. Millanvoye-van Brussel, and D. Duval Effect of oxygen deprivation on metabolism of arachidonic acid by cultures of rat heart cells Am. J. Physiol. 257 1989 H444 H451
6. D. Fulton, J.C. McGiff, M.S. Wolin, P. Kaminski, and J. Quilley Evidence against a cytochrome P450-derived reactive oxygen species as the mediator of the nitric oxide-independent vasodilator effect of bradykinin in the perfused heart of the rat J. Pharmacol. Exp. Ther. 280 1997 702 709
7. D.J. Granville, B. Tashakkor, C. Takeuchi, A.B. Gustafsson, C. Huang, M.R. Sayen, P. Wentworth Jr., M. Yeager, and R.A. Gottlieb Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors Proc. Natl. Acad. Sci. U. S. A. 101 2004 1321 1326
8. E.R. Gross, K. Nithipatikom, A.K. Hsu, J.N. Peart, J.R. Falck, W.B. Campbell, and G.J. Gross Cytochrome P450 omega-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel J. Mol. Cell. Cardiol. 37 2004 1245 1249
9. A.L. Hunter, R.P. Cruz, B.M. Cheyne, B.M. McManus, and D.J. Granville Cytochrome p450 enzymes and cardiovascular disease Can. J. Physiol. Pharm. 82 2004 1053 1060
10. K. Kobayashi, K. Urashima, N. Shimada, and K. Chiba Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA-expressed systems of the rat Drug Metab. Dispos. 31 2003 833 836
11. L.L. Leong, M.J. Sturm, Y. Ismail, C.J. Stephens, and R.R. Taylor Plasma phospholipase A2 activity in clinical acute myocardial infarction Clin. Exp. Pharmacol. Physiol. 19 1992 113 118
12. A.H. Lui, B.M. McManus, and I. Laher Endothelial and myogenic regulation of coronary artery tone in the mouse Eur. J. Pharmacol. 410 2000 25 31
13. A. Melet, N. Assrir, P. Jean, M. Pilar Lopez-Garcia, C. Marques-Soares, M. Jaouen, P.M. Dansette, M.A. Sari, and D. Mansuy Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid Arch. Biochem. Biophys. 409 2003 80 91
14. F.J. Miller Jr., D.D. Gutterman, C.D. Rios, D.D. Heistad, and B.L. Davidson Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis Circ. Res. 82 1998 1298 1305
15. K. Ogata, M.B. Jin, M. Taniguchi, T. Suzuki, T. Shimamura, N. Kitagawa, S. Magata, M. Fukai, H. Ishikawa, T. Ono, H. Furukawa, M. Fujita, and S. Todo Attenuation of ischemia and reperfusion injury of canine livers by inhibition of type II phospholipase A2 with LY329722 Transplantation 71 2001 1040 1046
16. V. Richard, T. Blanc, N. Keaffer, C. Tron, and C. Thuillez Myocardial and coronary endothelial protective effects of acetylcholine after myocardial ischaemia and reperfusion in rats: role of nitric oxide Br. J. Pharmacol. 8 1995 1532 1538
17. C.A. Sargent, O. Vesterqvist, J.R. McCullough, M.L. Ogletree, and G.J. Grover Effect of the phospholipase A2 inhibitors quinacrine and 7,7-dimethyleicosadienoic acid in isolated globally ischemic rat hearts J. Pharmacol. Exp. Ther. 262 1992 1161 1167
18. J. Seubert, B. Yang, J.A. Bradbury, J. Graves, L.M. Degraff, S. Gabel, R. Gooch, J. Foley, J. Newman, L. Mao, H.A. Rockman, B.D. Hammock, E. Murphy, and D.C. Zeldin Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway Circ. Res. 95 2004 506 514
19. P.L. Skarsgard, X. Wang, P. McDonald, A.H. Lui, E.K. Lam, B.M. McManus, C. van Breemen, and I. Laher Profound inhibition of myogenic tone in rat cardiac allografts is due to eNOS- and iNOS-based nitric oxide and an intrinsic defect in vascular smooth muscle contraction Circulation 101 2000 1303 1310
20. H. Toyoshima, Y. Nasa, Y. Kohsaka, Y. Isayama, F. Yamaguchi, A. Sanbe, and S. Takeo The effect of chronic treatment with trandolapril on cyclic AMP-and cyclic GMP-dependent relaxations in aortic segments of rats with chronic heart failure Br. J. Pharmacol. 123 1998 344 352
21. G.J. Van der Vusse, R.S. Reneman, and M. van Bilsen Accumulation of arachidonic acid in ischemic/reperfused cardiac tissue: possible causes and consequences Prostaglandins Leukot. Essent. Fat. Acids 57 1997 85 93
22. B. Wang, E. Brand-Schieber, B.A. Zand, X. Nguyen, J.R. Falck, N. Balu, and M.L. Schwartzman Cytochrome p450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors J. Pharmacol. Exp. Ther. 284 1998 966 973
23. J.F. Wang, Y. Yang, M.F. Sullivan, J. Min, J. Cai, D.C. Zeldin, Y.F. Xiao, and J.P. Morgan Induction of cardiac cytochrome p450 in cocaine-treated mice Exp. Biol. Med. (Maywood) 227 2002 182 188
24. X.L. Wang, M. Greco, A.S. Sim, N. Duarte, J. Wang, and D.E. Wilcken Effect of CYP1A1 MspI polymorphism on cigarette smoking related coronary artery disease and diabetes Atherosclerosis 162 2002 391 397
25. G.C. Wellman, A.D. Boney, M.T. Nelson, and J.E. Brayden Gender differences in coronary artery diameter involve estrogen, nitric oxide, and Ca(2+)-dependent K+ channels Circ. Res. 79 1996 1024 1030
26. S.D. Williams, and R.A. Gottlieb Inhibition of mitochondrial calcium-independent phospholipase A2 (iPLA2) attenuates mitochondrial phospholipid loss and is cardioprotective Biochem. J. 362 2002 23 32
27. S. Wu, W. Chen, E. Murphy, S. Gabel, K.B. Tomer, J. Foley, C. Steenbergen, J.R. Falck, C.R. Moomaw, and D.C. Zeldin Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes J. Biol. Chem. 272 1997 12551 12559
28. U. Yasar, A.M. Bennet, E. Eliasson, S. Lundgren, B. Wiman, U. De Faire, and A. Rane Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction Pharmacogenetics 13 2003 715 720